Kanban Zone Moves to Free Trial Mode
“We want to provide our users a comprehensive, yet easy-to-use tool that will help them achieve their goals more efficiently. We believe that adding the 30-Day Free Trial model will support this by allowing new subscribers and first-time users to take the time to get to know the tool (Kanban Zone), familiarize themselves with the Kanban method, and explore all Kanban Zone features, basic and advanced, and receive support and guidance in setting up their boards and using the full potential of Kanban Zone.” – says Dimitri Ponomareff, co-founder of Kanban Zone.
The main difference between the Free Plan and the Free Trial model is that the Free Trial model gives new users unrestricted access to all features for 30 days. The 3 existing plans: Personal, Start-Up and Enterprise are still available and have not changed. At any time during the Free Trial new users can select one of these 3 plans. The Personal plan is still free.
Kanban Zone, the most advanced online Kanban tool on the market, hopes that adding the Free Trial model can help teams and individuals to significantly improve the way they work, communicate and get work done. They continually work on improving the product and offering outstanding customer support.
The Free Trial rolled out on 20 November 2019. Now, as a holiday special, new subscribers can sign up for an extended 60-day Free Trial on the following link https://lnkd.in/g57MyFh.
7047 E. Greenway Parkway, Suite 250
Scottsdale, AZ 85254, USA
Kanban Zone was founded by two Agile coaches, seeking the best online Kanban tool for their clients. They built Kanban Zone based on their Kanban and Agile expertise. The tool provides the most effective online Kanban tool on the market, with the most advanced Kanban board editor and specialized templates to help you get started. The co-founders and constantly seek better ways to share, teach and implement new ways of working in all environments, and as a result, they constantly work on ways to improve Kanban Zone.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Kanban Zone Moves to Free Trial Mode here
News-ID: 1878806 • Views: 180
More Releases for Trial
Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
Global Clinical Trial Imaging Market
Global Clinical Trial Imaging Market is expected to reach USD 1297.39 Million by 2024 from USD 773.2 Million in 2016 at CAGR of 6.68% (Detailed analysis of the market CAGR is provided in the report). Global Clinical Trial Imaging Market is segmented by product & services, imaging modality, end user, and geography. Imaging Modality segment is classified as magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound and others. Computed Tomography
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Global Dysthymia Clinical Trial Market
The Dysthymia Clinical Trial Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Dysthymia is often characterized by chronic depression. Symptoms of dysthymia are the same as for depression and usually not as severe as major depression. Key symptom of dysthymia is daily
Thompson & Knight Expands Trial Practice
Dallas (August 15, 2011) – The global law firm of Thompson & Knight LLP is pleased to announce that Nathan H. Aduddell* has joined the Firm’s Trial Department as an Associate in the Dallas office. “Nathan comes to us with an excellent record of scholastic achievement and success in trial-related competitions, all accomplishments we believe will enhance his trial skills. We are very pleased to have him join